These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25749663)

  • 1. Targeted spontaneous reporting of suspected renal toxicity in patients undergoing highly active anti-retroviral therapy in two public health facilities in Uganda.
    Ndagije H; Nambasa V; Namagala E; Nassali H; Kajungu D; Sematiko G; Olsson S; Pal S
    Drug Saf; 2015 Apr; 38(4):395-408. PubMed ID: 25749663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
    Awodele O; Aliu R; Ali I; Oni Y; Adeyeye CM
    Pharmacol Res Perspect; 2018 Oct; 6(5):e00427. PubMed ID: 30324768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
    Ogar CK; Abiola A; Yuah D; Ibrahim A; Oreagba IA; Amadi EC; Adeyeye MC; Oshikoya KA
    Pharmaceut Med; 2019 Apr; 33(2):145-157. PubMed ID: 31933250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of adverse drug reaction signals in NAFDAC Pharmacovigilance activities from September to November, 2014.
    Awodele O; Ibrahim A; Orhii P
    Int J Risk Saf Med; 2016 Mar; 28(1):13-23. PubMed ID: 27176753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse Drug Reactions Reported to a National HIV & Tuberculosis Health Care Worker Hotline in South Africa: Description and Prospective Follow-Up of Reports.
    Njuguna C; Stewart A; Mouton JP; Blockman M; Maartens G; Swart A; Chisholm B; Jones J; Dheda M; Igumbor EU; Cohen K
    Drug Saf; 2016 Feb; 39(2):159-69. PubMed ID: 26547719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
    Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
    Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug reactions reported to a provincial public health sector pharmacovigilance programme in South Africa.
    Jones J; Swart A; Tommy E; Cohen K; Stewart A; Voget J; Blockman M
    S Afr Med J; 2020 Nov; 110(12):1226-1230. PubMed ID: 33403970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug reaction monitoring in patients on antiretroviral therapy in a tertiary care hospital in Eastern India.
    Mukherjee S; Era N; Saha B; Tripathi SK
    Indian J Pharmacol; 2017; 49(3):223-228. PubMed ID: 29033481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Effectiveness of Highly Active Antiretroviral Therapy in Treatment-Naïve HIV Patients: Preliminary Findings of a Cohort Event Monitoring Study in Belarus.
    Setkina S; Dotsenko M; Bondar S; Charnysh I; Kuchko A; Kaznacheeva A; Kozorez E; Dodaleva A; Rossa N
    Drug Saf; 2015 Apr; 38(4):365-72. PubMed ID: 25808626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses' reporting.
    Karlsson SA; Jacobsson I; Boman MD; Hakkarainen KM; Lövborg H; Hägg S; Jönsson AK
    Eur J Clin Pharmacol; 2015 May; 71(5):631-6. PubMed ID: 25845655
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implementation of a peer support intervention to promote the detection, reporting and management of adverse drug reactions in people living with HIV in Uganda: a protocol for a quasi-experimental study.
    Kiguba R; Ndagije HB; Nambasa V; Katureebe C; Zakumumpa H; Nanyonga SM; Ssanyu JN; Tregunno P; Harrison K; Merle CS; Raguenaud ME; Kitutu FE
    BMJ Open; 2022 May; 12(5):e056039. PubMed ID: 35589351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of monitoring adverse drug reactions in elderly patients: the results of a long-term pharmacovigilance programme.
    Carnovale C; Gentili M; Fortino I; Merlino L; Clementi E; Radice S; ViGer Group
    Expert Opin Drug Saf; 2016; 15(2):131-9. PubMed ID: 26882049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of Adverse Drug Reaction Profiles in Patients on Antiretroviral and Antitubercular Treatment in Zimbabwe.
    Masuka JT; Chipangura P; Nyambayo PP; Stergachis A; Khoza S
    Clin Drug Investig; 2018 Jan; 38(1):9-17. PubMed ID: 28965312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacovigilance of parenterally administered salvianolate based on analysis of spontaneous reporting system data].
    Lu PF; Xiang YY; Xie YM; Chang YP; Wang ZG
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):3003-7. PubMed ID: 24471320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reporting and recording of adverse drug reactions of highly active antiretroviral therapy by HIV infected patients and healthcare professionals respectively in the Ethekwini Metropolitan of Kwa-Zulu Natal, South Africa: a cross-sectional and retrospective comparative study.
    Zondi SL; Naidoo P
    Pan Afr Med J; 2022; 42():218. PubMed ID: 36845236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review.
    Okonkwo RI; Weidmann AE; Effa EE
    Drug Saf; 2016 Mar; 39(3):209-18. PubMed ID: 26692394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
    Fabbiani M; Mondi A; Colafigli M; D'Ettorre G; Paoletti F; D'Avino A; Ciccarelli N; Sidella L; Murri R; Fortuna S; Vullo V; Cauda R; De Luca A; Di Giambenedetto S
    Scand J Infect Dis; 2014 Jan; 46(1):34-45. PubMed ID: 24161018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse drug reactions in Ghanaian children: review of reports from 2000 to 2012 in VigiBase.
    Cliff-Eribo KO; Choonara I; Dodoo A; Darko DM; Sammons H
    Expert Opin Drug Saf; 2015; 14(12):1827-33. PubMed ID: 26436964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.